Previous 10 | Next 10 |
home / stock / dmttf / dmttf news
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuroscience company focused on psychedelic-assisted therapies for mental health conditions, announces its participation in th...
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the intensity and quality of the psychedelic experience LONDON, Feb. 22, 2022 (GLOBE N...
LONDON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“ DMT ”) therapies, has t...
LONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at...
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces its participation in the H.C. Wainwright 2...
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a no...
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies today confirms, following positive discussions with the U...
LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the LSX Inv...
Small Pharma (OTCPK:DMTTF): FQ2 GAAP EPS of -C$0.01. Press Release For further details see: Small Pharma reports FQ2 results
Company advances ongoing clinical trials with Phase I completed and dosing initiated in Phase IIa trial for lead product candidate, SPL026, a DMT-assisted therapy for the treatment of Major Depressive Disorder Fast-track Innovation Passport Designation awarded by the MHRA ...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...
2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to ...